Targeting Mycobacterium tuberculosis: Synthesis, in vitro and in silico evaluation of novel N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds

The development of novel antimycobacterial agents is an urgent challenge to eradicate the increasing emergence and rapid spread of multidrug‐resistant strains. Filamentous temperature‐sensitive protein Z (FtsZ) is a crucial cell division protein. Alteration of FtsZ assembly leads to cell division in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archiv der Pharmazie (Weinheim) 2023-08, Vol.356 (8), p.e2300187-n/a
Hauptverfasser: Zawal, Amira G., Abdel‐Aziz, Marwa M., El‐Shanawani, Abdalla A., Abdel‐Aziz, Lobna M., Taha, Mohamed, Simons, Claire, Elbaramawi, Samar S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 8
container_start_page e2300187
container_title Archiv der Pharmazie (Weinheim)
container_volume 356
creator Zawal, Amira G.
Abdel‐Aziz, Marwa M.
El‐Shanawani, Abdalla A.
Abdel‐Aziz, Lobna M.
Taha, Mohamed
Simons, Claire
Elbaramawi, Samar S.
description The development of novel antimycobacterial agents is an urgent challenge to eradicate the increasing emergence and rapid spread of multidrug‐resistant strains. Filamentous temperature‐sensitive protein Z (FtsZ) is a crucial cell division protein. Alteration of FtsZ assembly leads to cell division inhibition and cell death. To find novel antimycobacterial agents, a series of N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds 5a–o were synthesized. The activity of the compounds was evaluated against drug‐sensitive, multidrug‐resistant, and extensive‐drug‐resistant Mycobacterium tuberculosis. Compounds 5b, 5c, 5l, 5m, and 5o showed promising antimycobacterial activity with minimum inhibitory concentrations (MIC) in the range of 0.48–1.85 µg/mL and with low cytotoxicity against human nontumorigenic lung fibroblast WI‐38 cells. The activity of the compounds 5b, 5c, 5l, 5m, and 5o was evaluated against bronchitis causing‐bacteria. They exhibited good activity against Streptococcus pneumoniae, Klebsiella pneumoniae, Mycoplasma pneumonia, and Bordetella pertussis. Molecular dynamics simulations of Mtb FtsZ protein‐ligand complexes identified the interdomain site as the binding site and key interactions. ADME prediction indicated that the synthesized compounds have drug‐likeness. The density function theory studies of 5c, 5l, and 5n were performed to investigate E/Z isomerization. Compounds 5c and 5l are present as E‐isomers and 5n as an E/Z mixture. Our experimental outcomes provide an auspicious lead for the design of more selective and potent antimycobacterial drugs. A series of N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds were designed, synthesized, and evaluated against Mycobacterium tuberculosis strains, as well as against different bacteria‐causing bronchitis. Cytotoxicity was evaluated against human nontumorigenic lung fibroblast cells. Molecular dynamics simulations of Mtb filamentous temperature‐sensitive protein Z protein‐ligand complexes identified the interdomain site as the binding site.
doi_str_mv 10.1002/ardp.202300187
format Article
fullrecord <record><control><sourceid>proquest_wiley</sourceid><recordid>TN_cdi_proquest_miscellaneous_2823497857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2846877748</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1967-631e669cf8d712b51af1ccc17ce9aba9e270fb20d3d859a7743d9dc6579169483</originalsourceid><addsrcrecordid>eNpdUctO3TAQtVCRuIVuWVvqhkoE_EjsuDt0ebQSj6qlK1RFju1QI1872MmFsOIT2PQH-RJ8RcWCxZyZMzo6mtEBYBujPYwQ2ZdR93sEEYoQrvkamOGK4KLEdfkBzBBlVcEIpRvgY0o3CCGKSDUD_y5lvDaD9dfwbFKhlWow0Y4LOIytiWp0Idn0Ff6a_PDX5HEXWg-XdogBSq9XJFlnVYBmKd0oBxs8DB30YWkcPMfPj087rfEP4Ur_CffyIbi8Ibkm9yXjeZlBxslZbb2BKiz6MHqdtsB6J10yn_73TfD7-Ohy_q04vTj5Pj84LXosGC8YxYYxobpac0zaCssOK6UwV0bIVgpDOOpagjTVdSUk5yXVQitWcYGZKGu6CXZeffsYbkeThmZhkzLOSW_CmBpSE1oKXlc8Sz-_k96EMfp8XVaVrObZfWUoXlV31pmp6aNd5PcajJpVRM0qouYtoubg5-GPN0ZfACqHjp0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2846877748</pqid></control><display><type>article</type><title>Targeting Mycobacterium tuberculosis: Synthesis, in vitro and in silico evaluation of novel N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zawal, Amira G. ; Abdel‐Aziz, Marwa M. ; El‐Shanawani, Abdalla A. ; Abdel‐Aziz, Lobna M. ; Taha, Mohamed ; Simons, Claire ; Elbaramawi, Samar S.</creator><creatorcontrib>Zawal, Amira G. ; Abdel‐Aziz, Marwa M. ; El‐Shanawani, Abdalla A. ; Abdel‐Aziz, Lobna M. ; Taha, Mohamed ; Simons, Claire ; Elbaramawi, Samar S.</creatorcontrib><description>The development of novel antimycobacterial agents is an urgent challenge to eradicate the increasing emergence and rapid spread of multidrug‐resistant strains. Filamentous temperature‐sensitive protein Z (FtsZ) is a crucial cell division protein. Alteration of FtsZ assembly leads to cell division inhibition and cell death. To find novel antimycobacterial agents, a series of N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds 5a–o were synthesized. The activity of the compounds was evaluated against drug‐sensitive, multidrug‐resistant, and extensive‐drug‐resistant Mycobacterium tuberculosis. Compounds 5b, 5c, 5l, 5m, and 5o showed promising antimycobacterial activity with minimum inhibitory concentrations (MIC) in the range of 0.48–1.85 µg/mL and with low cytotoxicity against human nontumorigenic lung fibroblast WI‐38 cells. The activity of the compounds 5b, 5c, 5l, 5m, and 5o was evaluated against bronchitis causing‐bacteria. They exhibited good activity against Streptococcus pneumoniae, Klebsiella pneumoniae, Mycoplasma pneumonia, and Bordetella pertussis. Molecular dynamics simulations of Mtb FtsZ protein‐ligand complexes identified the interdomain site as the binding site and key interactions. ADME prediction indicated that the synthesized compounds have drug‐likeness. The density function theory studies of 5c, 5l, and 5n were performed to investigate E/Z isomerization. Compounds 5c and 5l are present as E‐isomers and 5n as an E/Z mixture. Our experimental outcomes provide an auspicious lead for the design of more selective and potent antimycobacterial drugs. A series of N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds were designed, synthesized, and evaluated against Mycobacterium tuberculosis strains, as well as against different bacteria‐causing bronchitis. Cytotoxicity was evaluated against human nontumorigenic lung fibroblast cells. Molecular dynamics simulations of Mtb filamentous temperature‐sensitive protein Z protein‐ligand complexes identified the interdomain site as the binding site.</description><identifier>ISSN: 0365-6233</identifier><identifier>EISSN: 1521-4184</identifier><identifier>DOI: 10.1002/ardp.202300187</identifier><language>eng</language><publisher>Frankfurt: Wiley Subscription Services, Inc</publisher><subject>arylidine compounds ; benzoxazole compounds ; Cell division ; FtsZ protein ; molecular dynamics ; Mycobacterium tuberculosis ; Proteins ; Streptococcus infections ; Tuberculosis</subject><ispartof>Archiv der Pharmazie (Weinheim), 2023-08, Vol.356 (8), p.e2300187-n/a</ispartof><rights>2023 Deutsche Pharmazeutische Gesellschaft.</rights><rights>2023 Deutsche Pharmazeutische Gesellschaft</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-8658-1296 ; 0000-0002-9487-1100</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fardp.202300187$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fardp.202300187$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Zawal, Amira G.</creatorcontrib><creatorcontrib>Abdel‐Aziz, Marwa M.</creatorcontrib><creatorcontrib>El‐Shanawani, Abdalla A.</creatorcontrib><creatorcontrib>Abdel‐Aziz, Lobna M.</creatorcontrib><creatorcontrib>Taha, Mohamed</creatorcontrib><creatorcontrib>Simons, Claire</creatorcontrib><creatorcontrib>Elbaramawi, Samar S.</creatorcontrib><title>Targeting Mycobacterium tuberculosis: Synthesis, in vitro and in silico evaluation of novel N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds</title><title>Archiv der Pharmazie (Weinheim)</title><description>The development of novel antimycobacterial agents is an urgent challenge to eradicate the increasing emergence and rapid spread of multidrug‐resistant strains. Filamentous temperature‐sensitive protein Z (FtsZ) is a crucial cell division protein. Alteration of FtsZ assembly leads to cell division inhibition and cell death. To find novel antimycobacterial agents, a series of N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds 5a–o were synthesized. The activity of the compounds was evaluated against drug‐sensitive, multidrug‐resistant, and extensive‐drug‐resistant Mycobacterium tuberculosis. Compounds 5b, 5c, 5l, 5m, and 5o showed promising antimycobacterial activity with minimum inhibitory concentrations (MIC) in the range of 0.48–1.85 µg/mL and with low cytotoxicity against human nontumorigenic lung fibroblast WI‐38 cells. The activity of the compounds 5b, 5c, 5l, 5m, and 5o was evaluated against bronchitis causing‐bacteria. They exhibited good activity against Streptococcus pneumoniae, Klebsiella pneumoniae, Mycoplasma pneumonia, and Bordetella pertussis. Molecular dynamics simulations of Mtb FtsZ protein‐ligand complexes identified the interdomain site as the binding site and key interactions. ADME prediction indicated that the synthesized compounds have drug‐likeness. The density function theory studies of 5c, 5l, and 5n were performed to investigate E/Z isomerization. Compounds 5c and 5l are present as E‐isomers and 5n as an E/Z mixture. Our experimental outcomes provide an auspicious lead for the design of more selective and potent antimycobacterial drugs. A series of N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds were designed, synthesized, and evaluated against Mycobacterium tuberculosis strains, as well as against different bacteria‐causing bronchitis. Cytotoxicity was evaluated against human nontumorigenic lung fibroblast cells. Molecular dynamics simulations of Mtb filamentous temperature‐sensitive protein Z protein‐ligand complexes identified the interdomain site as the binding site.</description><subject>arylidine compounds</subject><subject>benzoxazole compounds</subject><subject>Cell division</subject><subject>FtsZ protein</subject><subject>molecular dynamics</subject><subject>Mycobacterium tuberculosis</subject><subject>Proteins</subject><subject>Streptococcus infections</subject><subject>Tuberculosis</subject><issn>0365-6233</issn><issn>1521-4184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpdUctO3TAQtVCRuIVuWVvqhkoE_EjsuDt0ebQSj6qlK1RFju1QI1872MmFsOIT2PQH-RJ8RcWCxZyZMzo6mtEBYBujPYwQ2ZdR93sEEYoQrvkamOGK4KLEdfkBzBBlVcEIpRvgY0o3CCGKSDUD_y5lvDaD9dfwbFKhlWow0Y4LOIytiWp0Idn0Ff6a_PDX5HEXWg-XdogBSq9XJFlnVYBmKd0oBxs8DB30YWkcPMfPj087rfEP4Ur_CffyIbi8Ibkm9yXjeZlBxslZbb2BKiz6MHqdtsB6J10yn_73TfD7-Ohy_q04vTj5Pj84LXosGC8YxYYxobpac0zaCssOK6UwV0bIVgpDOOpagjTVdSUk5yXVQitWcYGZKGu6CXZeffsYbkeThmZhkzLOSW_CmBpSE1oKXlc8Sz-_k96EMfp8XVaVrObZfWUoXlV31pmp6aNd5PcajJpVRM0qouYtoubg5-GPN0ZfACqHjp0</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Zawal, Amira G.</creator><creator>Abdel‐Aziz, Marwa M.</creator><creator>El‐Shanawani, Abdalla A.</creator><creator>Abdel‐Aziz, Lobna M.</creator><creator>Taha, Mohamed</creator><creator>Simons, Claire</creator><creator>Elbaramawi, Samar S.</creator><general>Wiley Subscription Services, Inc</general><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8658-1296</orcidid><orcidid>https://orcid.org/0000-0002-9487-1100</orcidid></search><sort><creationdate>202308</creationdate><title>Targeting Mycobacterium tuberculosis: Synthesis, in vitro and in silico evaluation of novel N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds</title><author>Zawal, Amira G. ; Abdel‐Aziz, Marwa M. ; El‐Shanawani, Abdalla A. ; Abdel‐Aziz, Lobna M. ; Taha, Mohamed ; Simons, Claire ; Elbaramawi, Samar S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1967-631e669cf8d712b51af1ccc17ce9aba9e270fb20d3d859a7743d9dc6579169483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>arylidine compounds</topic><topic>benzoxazole compounds</topic><topic>Cell division</topic><topic>FtsZ protein</topic><topic>molecular dynamics</topic><topic>Mycobacterium tuberculosis</topic><topic>Proteins</topic><topic>Streptococcus infections</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zawal, Amira G.</creatorcontrib><creatorcontrib>Abdel‐Aziz, Marwa M.</creatorcontrib><creatorcontrib>El‐Shanawani, Abdalla A.</creatorcontrib><creatorcontrib>Abdel‐Aziz, Lobna M.</creatorcontrib><creatorcontrib>Taha, Mohamed</creatorcontrib><creatorcontrib>Simons, Claire</creatorcontrib><creatorcontrib>Elbaramawi, Samar S.</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Archiv der Pharmazie (Weinheim)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zawal, Amira G.</au><au>Abdel‐Aziz, Marwa M.</au><au>El‐Shanawani, Abdalla A.</au><au>Abdel‐Aziz, Lobna M.</au><au>Taha, Mohamed</au><au>Simons, Claire</au><au>Elbaramawi, Samar S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting Mycobacterium tuberculosis: Synthesis, in vitro and in silico evaluation of novel N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds</atitle><jtitle>Archiv der Pharmazie (Weinheim)</jtitle><date>2023-08</date><risdate>2023</risdate><volume>356</volume><issue>8</issue><spage>e2300187</spage><epage>n/a</epage><pages>e2300187-n/a</pages><issn>0365-6233</issn><eissn>1521-4184</eissn><abstract>The development of novel antimycobacterial agents is an urgent challenge to eradicate the increasing emergence and rapid spread of multidrug‐resistant strains. Filamentous temperature‐sensitive protein Z (FtsZ) is a crucial cell division protein. Alteration of FtsZ assembly leads to cell division inhibition and cell death. To find novel antimycobacterial agents, a series of N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds 5a–o were synthesized. The activity of the compounds was evaluated against drug‐sensitive, multidrug‐resistant, and extensive‐drug‐resistant Mycobacterium tuberculosis. Compounds 5b, 5c, 5l, 5m, and 5o showed promising antimycobacterial activity with minimum inhibitory concentrations (MIC) in the range of 0.48–1.85 µg/mL and with low cytotoxicity against human nontumorigenic lung fibroblast WI‐38 cells. The activity of the compounds 5b, 5c, 5l, 5m, and 5o was evaluated against bronchitis causing‐bacteria. They exhibited good activity against Streptococcus pneumoniae, Klebsiella pneumoniae, Mycoplasma pneumonia, and Bordetella pertussis. Molecular dynamics simulations of Mtb FtsZ protein‐ligand complexes identified the interdomain site as the binding site and key interactions. ADME prediction indicated that the synthesized compounds have drug‐likeness. The density function theory studies of 5c, 5l, and 5n were performed to investigate E/Z isomerization. Compounds 5c and 5l are present as E‐isomers and 5n as an E/Z mixture. Our experimental outcomes provide an auspicious lead for the design of more selective and potent antimycobacterial drugs. A series of N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds were designed, synthesized, and evaluated against Mycobacterium tuberculosis strains, as well as against different bacteria‐causing bronchitis. Cytotoxicity was evaluated against human nontumorigenic lung fibroblast cells. Molecular dynamics simulations of Mtb filamentous temperature‐sensitive protein Z protein‐ligand complexes identified the interdomain site as the binding site.</abstract><cop>Frankfurt</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/ardp.202300187</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0001-8658-1296</orcidid><orcidid>https://orcid.org/0000-0002-9487-1100</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0365-6233
ispartof Archiv der Pharmazie (Weinheim), 2023-08, Vol.356 (8), p.e2300187-n/a
issn 0365-6233
1521-4184
language eng
recordid cdi_proquest_miscellaneous_2823497857
source Wiley Online Library Journals Frontfile Complete
subjects arylidine compounds
benzoxazole compounds
Cell division
FtsZ protein
molecular dynamics
Mycobacterium tuberculosis
Proteins
Streptococcus infections
Tuberculosis
title Targeting Mycobacterium tuberculosis: Synthesis, in vitro and in silico evaluation of novel N1‐(benzo[d]oxazol‐2‐yl)‐N4‐arylidine compounds
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T23%3A00%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20Mycobacterium%20tuberculosis:%20Synthesis,%20in%20vitro%20and%20in%20silico%20evaluation%20of%20novel%20N1%E2%80%90(benzo%5Bd%5Doxazol%E2%80%902%E2%80%90yl)%E2%80%90N4%E2%80%90arylidine%20compounds&rft.jtitle=Archiv%20der%20Pharmazie%20(Weinheim)&rft.au=Zawal,%20Amira%20G.&rft.date=2023-08&rft.volume=356&rft.issue=8&rft.spage=e2300187&rft.epage=n/a&rft.pages=e2300187-n/a&rft.issn=0365-6233&rft.eissn=1521-4184&rft_id=info:doi/10.1002/ardp.202300187&rft_dat=%3Cproquest_wiley%3E2846877748%3C/proquest_wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2846877748&rft_id=info:pmid/&rfr_iscdi=true